• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Detection of pretreatment circulating tumor DNA as a biomarker of poor outcome in intermediate-risk rhabdomyosarcoma.

作者信息

Navid Fariba, Biegel Jaclyn A

机构信息

Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.

Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

出版信息

Transl Pediatr. 2024 May 31;13(5):869-872. doi: 10.21037/tp-24-7. Epub 2024 May 28.

DOI:10.21037/tp-24-7
PMID:38840688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11148749/
Abstract
摘要

相似文献

1
Detection of pretreatment circulating tumor DNA as a biomarker of poor outcome in intermediate-risk rhabdomyosarcoma.检测治疗前循环肿瘤DNA作为中危横纹肌肉瘤预后不良的生物标志物。
Transl Pediatr. 2024 May 31;13(5):869-872. doi: 10.21037/tp-24-7. Epub 2024 May 28.
2
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.循环肿瘤 DNA 对中危横纹肌肉瘤具有预后价值：来自儿童肿瘤学组的报告。
J Clin Oncol. 2023 May 1;41(13):2382-2393. doi: 10.1200/JCO.22.00409. Epub 2023 Feb 1.
3
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.循环肿瘤 DNA 在儿科横纹肌肉瘤中的分子特征：一项可行性研究。
JCO Precis Oncol. 2022 Oct;6:e2100534. doi: 10.1200/PO.21.00534.
4
Early detection of the PAX3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma.在肺泡横纹肌肉瘤病例中，循环肿瘤衍生 DNA 中 PAX3-FOXO1 融合基因的早期检测。
Genes Chromosomes Cancer. 2019 Aug;58(8):521-529. doi: 10.1002/gcc.22734. Epub 2019 Feb 10.
5
Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.使用针对断点的单克隆抗体检测肺泡横纹肌肉瘤中 PAX-FOXO1 融合蛋白。
Mod Pathol. 2021 Apr;34(4):748-757. doi: 10.1038/s41379-020-00719-0. Epub 2020 Dec 9.
6
Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.转移性横纹肌肉瘤的组织学、融合状态及预后：儿童肿瘤协作组报告
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26645. Epub 2017 May 18.
7
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.除了既定的临床预后预测因素外，利用 FOXO1 融合状态对儿童横纹肌肉瘤进行风险分层的精细化：来自儿童肿瘤学组的报告。
Cancer Med. 2019 Oct;8(14):6437-6448. doi: 10.1002/cam4.2504. Epub 2019 Aug 27.
8
Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.近期临床试验中局部 FOXO1 融合阳性横纹肌肉瘤患者的生存结局：儿童肿瘤学组软组织肉瘤委员会的报告。
Cancer. 2021 Mar 15;127(6):946-956. doi: 10.1002/cncr.33334. Epub 2020 Nov 20.
9
Outcome and prognostic variables in childhood rhabdomyosarcoma (RMS) with emphasis on impact of FOXO1 fusions in non-metastatic RMS: experience from a tertiary cancer centre in India.儿童横纹肌肉瘤（RMS）的结局和预后变量，重点关注FOXO1融合在非转移性RMS中的影响：来自印度一家三级癌症中心的经验
Ecancermedicalscience. 2023 Apr 27;17:1539. doi: 10.3332/ecancer.2023.1539. eCollection 2023.
10
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.PAX3/FOXO1 融合基因状态是横纹肌肉瘤的关键预后分子标志物，显著改善了当前的风险分层。
J Clin Oncol. 2012 May 10;30(14):1670-7. doi: 10.1200/JCO.2011.38.5591. Epub 2012 Mar 26.

本文引用的文献

1
Liquid biopsy in lung cancer.液体活检在肺癌中的应用。
Clin Chim Acta. 2024 Feb 1;554:117757. doi: 10.1016/j.cca.2023.117757. Epub 2024 Jan 4.
2
Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients.在因毒性而停止使用伊匹木单抗和纳武单抗治疗时可检测到的循环肿瘤DNA（ctDNA）预示着晚期黑色素瘤患者的疾病进展。
Front Oncol. 2023 Dec 19;13:1280730. doi: 10.3389/fonc.2023.1280730. eCollection 2023.
3
ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial.ctDNA 定量分析可改善高级别骨肉瘤患者结局的评估：来自 OS2006 试验的转化研究。
Ann Oncol. 2024 Jun;35(6):559-568. doi: 10.1016/j.annonc.2023.12.006. Epub 2023 Dec 22.
4
Liquid biopsy in colorectal cancer.结直肠癌中的液体活检
Clin Chim Acta. 2024 Jan 15;553:117674. doi: 10.1016/j.cca.2023.117674. Epub 2023 Nov 23.
5
Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse.采用多样本/多平台方法进行序贯基因组分析，以更好地界定横纹肌肉瘤的进展和复发情况。
NPJ Precis Oncol. 2023 Sep 20;7(1):96. doi: 10.1038/s41698-023-00445-1.
6
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.循环肿瘤 DNA 揭示了复发/难治性 ALK 驱动神经母细胞瘤患者对 lorlatinib 耐药的机制。
Nat Commun. 2023 May 5;14(1):2601. doi: 10.1038/s41467-023-38195-0.
7
Trimodality Treatment of Extremity Soft Tissue Sarcoma: Where Do We Go Now?肢体软组织肉瘤的三联疗法：我们现在何去何从？
Curr Treat Options Oncol. 2023 Apr;24(4):300-326. doi: 10.1007/s11864-023-01059-2. Epub 2023 Mar 6.
8
Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors.小儿实体瘤液体活检中的联合低通全基因组和靶向测序
NPJ Precis Oncol. 2023 Feb 20;7(1):21. doi: 10.1038/s41698-023-00357-0.
9
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.循环肿瘤 DNA 对中危横纹肌肉瘤具有预后价值：来自儿童肿瘤学组的报告。
J Clin Oncol. 2023 May 1;41(13):2382-2393. doi: 10.1200/JCO.22.00409. Epub 2023 Feb 1.
10
Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.无细胞游离 DNA 作为儿科横纹肌肉瘤的诊断和预后生物标志物。
JCO Precis Oncol. 2023 Jan;7:e2200113. doi: 10.1200/PO.22.00113.